NCT00639002View on ClinicalTrials.gov

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Ruxolitinib 25 mg

Ruxolitinib was supplied as 5 and 25 mg tablets.

DRUG

Dexamethasone 40 mg

Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.

Trial Locations (3)

10011

New York

33435

Boynton Beach

92346

Highland

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT00639002 - A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter